MA26.02 Upfront or Sequential Strategy for New Generation Anaplastic Lymphoma Kinase (ALK) Inhibitors: An Italian Retrospective Study.

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.539
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Anaplastic Lymphoma Kinase (ALK)

Science-Business eXchange
2008English

Development of Anaplastic Lymphoma Kinase (ALK) Inhibitors and Molecular Diagnosis in ALK Rearrangement-Positive Lung Cancer

OncoTargets and Therapy
OncologyPharmacology
2014English

Anaplastic Lymphoma Kinase (ALK) Inhibitors for Second-Line Therapy of Non-Small Cell Lung Cancer

Lung Cancer: Targets and Therapy
Oncology
2012English

Anaplastic Lymphoma Kinase Confers Resistance to BRAF Kinase Inhibitors in Melanoma

iScience
Multidisciplinary
2019English

ALK (Anaplastic Lymphoma Kinase, CD246)-specific CARs: New Immunotherapeutic Agents for the Treatment of Pediatric Solid Tumors

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2013English

ALK-negative Anaplastic Large Cell Lymphoma

2020English

Status of the Anaplastic Lymphoma Kinase (ALK) Gene in Inflammatory Breast Carcinoma

SpringerPlus
Multidisciplinary
2013English

Pcn198 - An Economic Systematic Literature Review (Slr) for Anaplastic Lymphoma Kinase-Positive (Alk+) Non-Small-Cell Lung Cancer (Nsclc)

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

P1.15-16 ALKConnect: An Anaplastic Lymphoma Kinase Positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Patient Insights Network

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy